Hypokalemia and sodium retention in patients with diabetes and chronic hepatitis receiving insulin and glycyrrhizin.
Of 9 patients with chronic hepatitis treated with intravenous administration of 40 to 200 mg/day of glycyrrhizin, 3 diabetic patients receiving concomitant insulin developed hypokalemia, sodium retention and suppression of both plasma aldosterone concentration and plasma renin activity after the administration for 3 to 6 days. In the remaining 6 patients (5 nondiabetic and 1 diabetic) receiving no insulin, the administration over the long term (18 to 266 days) never caused these abnormalities. The development of hypokalemia and sodium retention in the patients was not associated with increased urinary excretion of potassium, indicating a different condition from pseudoaldosteronism caused by the desoxycorticosterone-like action of glycyrrhizin. These findings suggest that insulin which is known to have hypokalemic, antinatriuretic and antikaliuretic activity, as well as glycyrrhizin plays an important pathogenetic role in the observed electrolyte disturbance, and suppression of both renin and aldosterone.
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019695:Glycyrrhizic Acid; D006505:Hepatitis / Q000188:drug therapy*; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000378:metabolism*
D000998:Antiviral Agents; D007328:Insulin; D019695:Glycyrrhizic Acid; D012964:Sodium; D006034:Glycyrrhetinic Acid